An Association Study of Polymorphisms in JAK3 Gene with Lung Cancer in the Korean Population

Wonbeak YOO; Hae-Yun JUNG; Seungjoon LIM; Jae-Sook SUNG; Kyong-Hwa PARK; Jeong-Seon RYU; Sang-Won SHIN; Jun-Suk KIM; Jae-Hong SEO; Yeul-Hong KIM.
Cancer Research and Treatment ; : 108-116, 2011.
Artículo en Inglés | WPRIM | ID: wpr-78353

Documentos relacionados

  1. Docking and Selectivity Studies of Covalently Bound Janus Kinase 3 Inhibitors.
  2. JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling.
  3. JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016-present).
  4. JAK3 Inhibition Regulates Stemness and Thereby Controls Glioblastoma Pathogenesis.
  5. Eyes on Topical Ocular Disposition: The Considered Design of a Lead Janus Kinase (JAK) Inhibitor That Utilizes a Unique Azetidin-3-Amino Bridging Scaffold to Attenuate Off-Target Kinase Activity, While Driving Potency and Aqueous Solubility.
  6. N-Acetylcysteine Alters Disease Progression and Increases Janus Kinase Mutation Frequency in a Mouse Model of Precursor B-Cell Acute Lymphoblastic Leukemia.
  7. Janus Kinase 3 (JAK3): A Critical Conserved Node in Immunity Disrupted in Immune Cell Cancer and Immunodeficiency.
  8. Janus Kinase 3 phosphorylation and the JAK/STAT pathway are positively modulated by follicle-stimulating hormone (FSH) in bovine granulosa cells.
  9. JAK mutations in high-risk childhood acute lymphoblastic leukemia.
  10. The γ<sub>c</sub> Family of Cytokines: Basic Biology to Therapeutic Ramifications.